Apnimed, Inc.

NasdaqGS:APMD Stock Report

Market Cap: US$1.1b

Apnimed Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Kevin Lind

Chief executive officer

US$508.2k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3.3yrs
Board average tenure2.4yrs

Recent management updates

No updates

Recent updates

Seeking Alpha • Sep 10

Apnimed: What We Know Heading Into The Feb PDUFA

Summary Apnimed, Inc. (APMD) is a late-stage, de-risked regulatory play with a fully funded path to commercialisation, focused on AD109 for obstructive sleep apnea (OSA). AD109 (Oxnimbi) demonstrated robust Phase 3 efficacy, clear differentiation from CPAP, and manageable safety, with an NDA under FDA review and a February 2027 PDUFA date. APMD's financials show a transition from R&D to pre-commercial buildout, with a strong cash position and multiple years of runway to support launch activities. The investment thesis hinges on successful approval, rapid adoption in a large untreated OSA market, and execution risk around payer dynamics and real-world uptake. Read the full article on Seeking Alpha

CEO

Kevin Lind (50 yo)

less than a year
Tenure
US$508,156
Compensation

Mr. Kevin Robert Lind is Chief Executive Officer of Apnimed, Inc. from June 2, 2026 and serves as its Director from March 2025. Mr. Lind served as Non-Executive Chairman of the Board of Apnimed, Inc. since...

Leadership Team

NamePositionTenureCompensationOwnership
Kevin Lind
CEO & Directorless than a yearUS$508.16kno data
Lawrence Miller
Founder & Vice Chair of the Board8.7yrsUS$1.31m1.1%
$ 12.0m
Dennis Molnar
President & COO8.1yrsUS$724.84k0.14%
$ 1.5m
Luigi Montemurro
Co-Founder & Chief Scientific Officer5.5yrsno datano data
Michael Kelly
Chief Financial Officerless than a yearno datano data
Leila Sylvain
Senior Manager of Administration4.1yrsno datano data
Steven Spector
Chief Legal Officer & Head of Corporate Affairsless than a yearno datano data
Jennifer Patterson
Senior Vice President of Human Resourcesless than a yearno datano data
John Cronin
Chief Medical Officer3.9yrsno datano data
Sean Johnston
Consulting Head of CMC3.7yrsno datano data
John Yee
Senior Vice President of Medical Affairs3yrsno datano data
Graham Goodrich
Chief Commercial Officer2.7yrsno datano data
3.3yrs
Average Tenure
57.5yo
Average Age

Experienced Management: APMD's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kevin Lind
CEO & Director1.5yrsUS$508.16kno data
Lawrence Miller
Founder & Vice Chair of the Board8.7yrsUS$1.31m1.1%
$ 12.0m
Paul Sekhri
Independent Chair of the Boardless than a yearno data0.030%
$ 327.9k
Gary Sender
Independent Director1.9yrsno data0%
$ 0
Chris Dimitropoulos
Independent Director3.7yrsno datano data
Douglas Kirsch
Member of Medical Advisory Boardno datano datano data
Paul Fonteyne
Independent Director2.9yrsno data0%
$ 0
Danny Eckert
Member of Medical Advisory Boardno datano datano data
Susan Redline
Member of Medical Advisory Boardno datano datano data
Sanjay Patel
Member of Medical Advisory Boardno datano datano data
Nathaniel Watson
Member of Medical Advisory Boardno datano datano data
Dennis Hwang
Member of Medical Advisory Boardno datano datano data
2.4yrs
Average Tenure
65yo
Average Age

Experienced Board: APMD's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 21:30
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apnimed, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Joshua SchimmerCantor Fitzgerald & Co.
Umer RaffatEvercore ISI